Engineering De Novo Miniprotein GPCR Modulators to Unlock Novel Therapeutic Opportunities
12:00 pm - Tuesday 2nd March 2027
- Combining protein design with genetically encoded high-throughput screening to accelerate the discovery of functional GPCR agonists and antagonists
- Expanding the druggable GPCR landscape by engineering miniproteins against previously challenging and underexplored receptors
- Advancing miniproteins as a therapeutic modality to deliver differentiated selectivity, functionality and drug-like properties
